重磅发布!2020版GOLD COPD指南出炉!

2019-11-14 医咖会 医咖会

近日,GOLD官网发布了2020版GOLD COPD(慢性阻塞性肺疾病全球倡议)报告。最新的指南基于2018年1月至2019年7月间的关键研究证据进行了更新,相比2019年指南,增加了62篇新文献。报告全文下载链接:https://goldcopd.org/gold-reports/不方便下载的伙伴,可在文章下方留言中留下邮箱,小咖把GOLD 2020报告全文发给你~在2019版指南中,将患者

近日,GOLD官网发布了2020版GOLD COPD(慢性阻塞性肺疾病全球倡议)报告。最新的指南基于2018年1月至2019年7月间的关键研究证据进行了更新,相比2019年指南,增加了62篇新文献。



报告全文下载链接:

https://goldcopd.org/gold-reports/

不方便下载的伙伴,可在文章下方留言中留下邮箱,小咖把GOLD 2020报告全文发给你~

在2019版指南中,将患者初始治疗(基于ABCD)与随访治疗(基于患者主要特点和当前使用药物)分开。此外,指南推荐嗜酸性粒细胞数作为吸入糖皮质激素预防COPD加重的疗效评估标志物。

2020版GOLD指南的基本原则与上一版一致。最主要的改变为:改进了非药物治疗的使用;嗜酸性粒细胞作为疗效评估标志物方面增加了更多信息;更加清晰阐明了急性加重的诊断。此外,指南不再提哮喘-慢阻肺重叠(ACO),而是强调哮喘和COPD是不同的疾病,不过这两者可能会有共同的特征(例如,嗜酸性粒细胞增多,一定程度的可逆性)。

在以下章节新增了图表:① 起始ICS治疗时需考虑的因素(图3.1);② COPD的管理(图4.1);③ 非药物治疗的随访(图4.10);④ COPD加重的鉴别诊断(表5.1)。

对指南中的一些核心要点(Key Points)和推荐意见进行了编辑整理,希望能对大家有所帮助。

第一章  定义和概述

核心要点

1、慢性阻塞性肺疾病(COPD)是一种可以预防和治疗的常见病,以持续存在的呼吸道症状和气流受限为特征,由于显着暴露于有害颗粒物或气体造成的气道和/或肺泡异常所引起。

2、呼吸困难、咳嗽和/或咳痰是最常见的症状;患者可能漏报这些症状。

3、吸烟是COPD主要的危险因素,但是环境暴露例如生物燃料和空气污染也是重要因素。除了危险因素暴露,还有宿主因素(如遗传异常,肺部发育异常和加速老化)也会导致个体易发生COPD。

4、COPD患者可能会出现呼吸道症状的急性恶化,从而病情发生显着改变,称之为“COPD 急性加重”。

5、大多数患者中,COPD会伴随很多慢性病,导致患病和病死率增加。

第二章  诊断和初始评估

核心要点

1、任何有呼吸困难,慢性咳嗽或咳痰,有反复下呼吸道感染史,和/或有危险因素暴露史的患者,需考虑COPD这一诊断。

2、需通过肺功能检查来确诊COPD;使用支气管扩张剂后,FEV1/FVC<0.70,确认存在持续性气流受限。

3、COPD评估的目标是确定气流受限的程度,疾病对患者健康状况的影响,以及未来事件(例如急性加重,入院或死亡)的发生风险,以对治疗进行指导。

4、COPD通常合并其他慢性疾病,包括心血管疾病、骨骼肌功能障碍、代谢综合征骨质疏松症、抑郁、焦虑和肺癌。这些合并症可能独立影响COPD的死亡和入院,因此需要经常评估和恰当治疗。

第三章 预防和维持治疗的支持证据

核心要点

1、戒烟是关键。药物治疗和尼古丁替代疗法可以提高长期戒烟率。立法禁烟,以及医务人员提供戒烟咨询可提供戒烟率。

2、电子香烟辅助戒烟的有效性和安全性目前还不确定。

3、药物治疗可以缓解COPD症状,降低急性加重的频率和严重程度,改善患者健康状况和运动耐力。

4、每一种药物治疗方案应该个体化,应基于以下情况考虑:患者症状的严重程度,急性加重风险,副作用,合并症,药物可用性和成本,患者对治疗的反应、个人意愿和使用不同给药装置的能力。

5、吸入装置使用技术需要定期评估。

6、接种流感疫苗和肺炎球菌疫苗可降低下呼吸道感染的发生率。

7、肺康复治疗可以改善患者症状、生活质量和日常活动中的生理和情感参与。

8、静息状态下重度慢性低氧血症的患者,长期氧疗可以改善生存。

9、静息状态下或运动诱发的中度氧饱和度下降的COPD稳定期患者,不应常规进行长期氧疗。但也要考虑到患者个体需求。

10、重度慢性高碳酸血症和有急性呼吸衰竭入院史的患者,长期无创通气可能降低死亡率并预防再入院。

11、最佳药物治疗效果仍不佳的部分晚期肺气肿患者,外科或支气管镜介入治疗可能有益。

12、姑息治疗方法对于控制晚期COPD患者的症状是有效的。

第四章 COPD稳定期的管理

核心要点

1、COPD稳定期的管理策略应基于对患者症状和未来急性加重风险的个体化评估来制定。

2、所有吸烟者都应支持戒烟。

3、主要治疗目标是减少症状和未来急性加重的发生风险。

4、管理策略包括药物和非药物干预手段。

第五章  COPD急性加重的管理

核心要点

1、COPD急性加重,是指呼吸道症状的急性恶化,需要额外的治疗。

2、因为症状非COPD特有,应该考虑相关的鉴别诊断。

3、一些因素可导致COPD的急性加重,最常见的原因是呼吸道感染。

4、COPD急性加重治疗的目标是尽可能减少急性加重的不良影响,预防后续事件的发生。

5、吸入短效β2受体激动剂,伴或不伴短效抗胆碱能药物,推荐作为急性加重的起始支气管扩张剂治疗。

6、出院前应该尽早开始长效支气管扩张剂维持治疗。

7、全身应用糖皮质激素可以改善肺功能(FEV1)和氧合,缩短恢复时间和住院时长。疗程不应超过5-7天。

8、如有指征时可以使用抗生素,能够缩短恢复时间,降低早期复发、治疗失败的风险,缩短住院时长。疗程应为5-7天。

9、由于甲基黄嘌呤存在副作用,不推荐使用。

10、发生急性呼吸衰竭的COPD患者,在无绝对禁忌证时,无创机械通气是首选的机械通气模式。因为无创通气能改善气体交换、减少插管、缩短住院时间和改善生存。

11、患者出现过一次急性加重发作后,应该开始采取适当的预防急性加重发作的措施。

第六章  COPD和合并症

核心要点

1、COPD常与其他疾病共存,对疾病进程产生显着影响。

2、一般来说,存在合并症不应改变COPD的治疗方案,而不论有无COPD,合并症的治疗应该选择标准治疗方案。

3、COPD患者常并发肺癌,也是患者死亡的主要原因。

4、心血管疾病是COPD常见和重要的合并症。

5、骨质疏松症、抑郁/焦虑是COPD常见的重要合并症,容易漏诊,与健康状态及预后不佳相关。

6、食管反流(GERD)与急性加重风险升高及健康状态较差相关。

7、当COPD是多疾病诊疗计划中的一部分时,应注意确保治疗的简洁性和最小化用药。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2022-06-10 1462906em49暂无昵称

    求一份指南,谢谢 627251242*******

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2021-11-14 ms4000001082186280

    求一份指南 945362262@qq.com

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2021-08-15 Helen

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2021-01-07 ms3000000837548309

    2205968670@**.com

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-12-01 ms6000001296915076

    求,752013872@**.com

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-11-09 ms5000000457467107

    求一份指南,1356675176@**.com

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-09-24 ms7000000839970463

    求一份指南,1427882581@(QQ号).com

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-09-24 ms7000000839970463

    求一份指南,1427882581@**.com

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-08-10 ms5000001041042825

    727892618@**.com,求一份指南

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1225692, encodeId=e9c81225692a2, content=求一份指南,谢谢 627251242*******, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a25116878, createdName=1462906em49暂无昵称, createdTime=Fri Jun 10 17:39:07 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070044, encodeId=942a10e004479, content=求一份指南 945362262@qq.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c3f5710361, createdName=ms4000001082186280, createdTime=Sun Nov 14 02:33:14 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007949, encodeId=547b100e949ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210815/31c63501204649ecb2d87ce62336c70f/cd0f5a6cd7eb48559b767672a778bb4d.jpg, createdBy=cc385307017, createdName=Helen, createdTime=Sun Aug 15 00:53:46 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914352, encodeId=8a4f91435218, content=2205968670@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b3f5450829, createdName=ms3000000837548309, createdTime=Thu Jan 07 12:27:18 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904077, encodeId=54bf9040e7a1, content=求,752013872@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31745400749, createdName=ms6000001296915076, createdTime=Tue Dec 01 23:21:24 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898129, encodeId=449389812929, content=求一份指南,1356675176@**.com , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58555433353, createdName=ms5000000457467107, createdTime=Mon Nov 09 23:50:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888073, encodeId=bd8e8880e3f9, content=求一份指南,1427882581@(QQ号).com, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:17:57 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888069, encodeId=aad188806973, content=求一份指南,1427882581@**.com, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=372a5421380, createdName=ms7000000839970463, createdTime=Thu Sep 24 21:16:48 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807232, encodeId=c8dc80e232fd, content=727892618@**.com,求一份指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8f5409924, createdName=ms5000001041042825, createdTime=Mon Aug 10 10:19:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601416, encodeId=85c26014160e, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6dd2511128, createdName=124bcb9dm45暂无昵称, createdTime=Thu Jun 04 21:09:16 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-06-04 124bcb9dm45暂无昵称

    ***

    0

相关资讯

2017年GOLD慢性阻塞性肺疾病定义和诊断的全球策略解读

1998 年慢性阻塞性肺疾病(慢阻肺)全球创议(Global Initiative for Chronic Obstructive Lung Disease,GOLD)启动,其目标是根据已发表的最佳研究结果制订慢阻肺的管理推荐。第 1 版慢阻肺诊断、治疗及预防的全球策略于 2001 年发布,2006 年和 2011 年分别根据已发表的研究进行了全面修订。GOLD 2011修订版的修订分别于 2

J Endod:WaveOne Gold往返及Twisted File自适应系统预备弯曲根管中碎屑推出根尖孔的比较

这篇研究的目的是为了评估弯曲根管内不同运动对碎屑推出根尖孔的影响。

2011 版GOLD报告修订要点解读

作者:北京大学第三医院呼吸科 姚婉贞 常春  慢性阻塞性肺疾病全球创议(GOLD)报告由美国国立心、肺、血液研究所和世界卫生组织于2001年4月首次发表,每5年修订一次,并每年进行更新。2011年版的GOLD在内容上做了较多修订,增加了治疗策略和合并症的新章节,对慢性阻塞性肺疾病(COPD)评估和治疗建议更为明确。本文将对更新要点进行解读。   肺功能测定   肺功能测定是确诊COPD的必要

一篇文章帮你读懂所有GOLD 2017更新 - 再也不怕科主任提问啦!

《慢阻肺诊断、治疗与预防全球倡议(GOLD)》2017版已于近日正式发布。本次更新是六年来的首次重大更新。本期小编将为大家梳理GOLD 2017版的更新要点。诸位看官莫急,待小编给你娓娓道来。

精品指南:2017 GOLD慢性阻塞性肺疾病全球倡议解读,全新专家解读视频免费送!

慢性阻塞性肺疾病全球倡议组织最新发布了2017版GOLD慢阻肺诊断治疗和预防的全球策略报告,文章包括对已经发布的2015版和2016版的更新。更新主要包括6部分内容。 【指南全文】 2017 GOLD慢性阻塞性肺疾病全球倡议:COPD诊断、治疗与预防全球策略 【指南解读】 自从2001年慢性阻塞性肺疾病全球倡议(GOLD)颁布第1版慢性阻塞性肺疾病诊断、处理和预防全球策

这些慢阻肺新病情评估方法尚未收录入GOLD 2018,它们对患者预后有何指导意义?

近期已有评估新分组方法的文献报道,但并未收录入GOLD 2018。本文对慢阻肺新病情评估做一综述。